AMPH
NASDAQ · Pharmaceuticals
Amphastar Pharmaceuticals In
$28.02
+0.90 (+3.32%)
Financial Highlights (FY 2026)
Revenue
626.97M
Net Income
85.43M
Gross Margin
49.5%
Profit Margin
13.6%
Rev Growth
+13.0%
D/E Ratio
0.77
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 49.5% | 49.5% | 67.8% | 67.8% |
| Operating Margin | 19.5% | 17.5% | 20.8% | 20.4% |
| Profit Margin | 13.6% | 13.0% | 17.8% | 18.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 626.97M | 554.89M | 348.56M | 350.56M |
| Gross Profit | 310.10M | 274.45M | 236.21M | 237.56M |
| Operating Income | 122.26M | 97.38M | 72.44M | 71.64M |
| Net Income | 85.43M | 68.05M | 62.09M | 65.15M |
| Gross Margin | 49.5% | 49.5% | 67.8% | 67.8% |
| Operating Margin | 19.5% | 17.5% | 20.8% | 20.4% |
| Profit Margin | 13.6% | 13.0% | 17.8% | 18.6% |
| Rev Growth | +13.0% | +13.0% | -2.5% | +16.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 256.64M | 256.64M | 168.00M | 150.95M |
| Total Equity | 331.66M | 331.66M | 806.96M | 710.94M |
| D/E Ratio | 0.77 | 0.77 | 0.21 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 135.00M | 113.50M | 110.01M | 124.87M |
| Free Cash Flow | — | — | 39.29M | 36.18M |